Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation.
暂无分享,去创建一个
C. Masters | A. Hill | R. Cappai | M. Fodero-Tavoletti | D. Galatis | K. Barnham | Keyla A. Perez | C. L. Pham | F. Ali | S. L. Leong
[1] C. Masters,et al. Dimeric structures of alpha-synuclein bind preferentially to lipid membranes. , 2008, Biochimica et biophysica acta.
[2] A. C. Belin,et al. Parkinson’s disease: A genetic perspective , 2008, The FEBS journal.
[3] R. Cappai,et al. Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity , 2008, Neurochemical Research.
[4] N. Brot,et al. Methionine Sulfoxide Reductase A and a Dietary Supplement S-Methyl-L-Cysteine Prevent Parkinson's-Like Symptoms , 2007, The Journal of Neuroscience.
[5] H. Ischiropoulos,et al. Cellular Oligomerization of α-Synuclein Is Determined by the Interaction of Oxidized Catechols with a C-terminal Sequence* , 2007, Journal of Biological Chemistry.
[6] S. Bottomley,et al. Dopamine promotes α‐synuclein aggregation into SDS‐resistant soluble oligomers via a distinct folding pathway , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] Jun Hu,et al. Inhibition of α‐synuclein fibrillization by dopamine analogs via reaction with the amino groups of α‐synuclein , 2005 .
[8] J. Trojanowski,et al. Reversible Inhibition of α-Synuclein Fibrillization by Dopaminochrome-mediated Conformational Alterations* , 2005, Journal of Biological Chemistry.
[9] Jochen Klucken,et al. Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.
[10] Jie Li,et al. Dopamine and L‐dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[11] V. Uversky,et al. Role of individual methionines in the fibrillation of methionine-oxidized α-synuclein , 2004 .
[12] C. Masters,et al. Structure of the Alzheimer's Disease Amyloid Precursor Protein Copper Binding Domain , 2003, The Journal of Biological Chemistry.
[13] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[14] Patrik Brundin,et al. Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein , 2002, Nature Reviews Neuroscience.
[15] Bruce A. Yankner,et al. Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson disease , 2002, Nature Medicine.
[16] V. Uversky,et al. Methionine oxidation inhibits fibrillation of human α‐synuclein in vitro , 2002 .
[17] D. Sulzer. α-synuclein and cytosolic dopamine: Stabilizing a bad situation , 2001, Nature Medicine.
[18] Peter T. Lansbury,et al. Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct , 2001, Science.
[19] A. Goldberg,et al. PAN, the proteasome-activating nucleotidase from archaebacteria, is a protein-unfolding molecular chaperone , 2000, Nature Cell Biology.
[20] Sarah J. Tabrizi,et al. Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity , 2000 .
[21] P. Lansbury,et al. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.
[22] Heidi Phillips,et al. Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.
[23] P. Lansbury,et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[24] E. Masliah,et al. Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease* , 1999, The Journal of Biological Chemistry.
[25] J. Growdon,et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies , 1999, Neurology.
[26] M. Citron,et al. Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.
[27] E. Masliah,et al. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro , 1999 .
[28] M. LaVoie,et al. Dopamine Quinone Formation and Protein Modification Associated with the Striatal Neurotoxicity of Methamphetamine: Evidence against a Role for Extracellular Dopamine , 1999, The Journal of Neuroscience.
[29] Ralph A. Bradshaw,et al. N-Terminal processing: the methionine aminopeptidase and Nα-acetyl transferase families , 1998 .
[30] E. Masliah,et al. Non-A beta component of Alzheimer's disease amyloid (NAC) is amyloidogenic. , 1995, Biochemistry.
[31] Akihiko Iwai,et al. The precursor protein of non-Aβ component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system , 1995, Neuron.
[32] E. Masliah,et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[33] R. Scheller,et al. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[34] K. Myambo,et al. Processing of the initiation methionine from proteins: properties of the Escherichia coli methionine aminopeptidase and its gene structure , 1987, Journal of bacteriology.
[35] W. Vogt. Oxidation of methionyl residues in proteins: tools, targets, and reversal. , 1995, Free radical biology & medicine.